



FOR RELEASE, February 1st, 2007

Contact: Trinity Biotech plc
Brendan K. Farrell
(353) -1-2769803
e-mail: brendan.farrell@trinitybiotech.com

Trinity Biotech Announces Strategic Partnership with Leading New York City Based Provider of Community-Focused Primary Care

DUBLIN, IRELAND--(MARKET WIRE)— February 1st, 2007 -- Trinity Biotech plc (NASDAQ:[TRIB](#) - [News](#)) (DUBLIN: TRIB.I), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced a strategic partnership with Community Healthcare Network (CHN) <http://chnnyc.org/> of New York City to introduce Uni-Gold <http://www.unigoldhiv.com/> rapid HIV testing across the CHN network of health clinics in the boroughs of Bronx, Brooklyn, Manhattan and Queens.

Community Healthcare Network (CHN) is a not-for-profit organization providing access to affordable, culturally-competent and comprehensive community-based primary care, mental health and social services for diverse populations in underserved communities throughout New York City. CHN serves more than 60,000 individuals a year who would otherwise have little or no access to critical health care. Managing the HIV Program and Services Division of CHN is Dr. Luis Freddy Molano, a recognized expert in the field of HIV testing.

"Community Healthcare Network has been providing high quality, primary health care, social services and mental health care in some of the most underserved neighborhoods in New York City for more than 25 years," said Catherine M. Abate, President & CEO. "This exciting partnership with Trinity Biotech and the introduction of Uni-Gold rapid HIV testing will expand on our mission to provide high quality healthcare, mental health and social services to thousands of New Yorkers regardless of ability to pay."

Commenting on the announcement, Brendan Farrell, President, said, "Trinity is honored to work with CHN to introduce Uni-Gold throughout New York City. Teaming with the more than three hundred CHN staff, including medical providers, nurses, nutritionists, social workers, case managers, and counselors to introduce a fast, simple to use, and highly accurate, rapid HIV test is part of our strategic plan to make Uni-Gold a routine part of care so all Americans can know their HIV status."

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own sales force and a network of international distributors and strategic partners.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact:

Trinity Biotech plc
Brendan Farrell
+ 353 1 276 9803
E-mail: brendan.farrell@trinitybiotech.com

Contact:

Community Healthcare Network (CHN)
Elizabeth N. Howell
(212) 545-2404
E-mail: ehowell@chnnyc.org